AbbVie has collaborated with the International Myeloma Foundation (IMF) to perform a retrospective chart review study to gain insights into multiple myeloma (MM) and better manage the disease.
MM is the second most common blood cancer and affects plasma cells in bone marrow. The cells become cancerous, grow uncontrollably and generate abnormal proteins, which can lead to tumours.
Go deeper with GlobalData
Approximately 86,000 people suffer from MM globally each year and the median survival rate is between 29 and 62 months.
The partners intend to focus on the relatively unknown role of genetic mutations in response to therapy and the associated patient outcomes.
IMF chairman Brian Durie said: “There are significant knowledge gaps about multiple myeloma, and among these gaps is the role of genetic mutations in response to treatment, and the related outcomes for patients.
“This study has the potential to provide valuable real-world evidence that can help advance care for patients, and we are proud to join forces with AbbVie to further advance efforts in research and education in multiple myeloma.”
The study is set to include 1,500 MM patients who have the t(11;14) translocation that is found in 16-24% of FISH- MM cases. IMF researchers from a minimum of 30 participating centres will review and characterise the outcomes in these patients.
The primary objective of the study is overall survival, and the secondary objectives are response rates, duration of responses, progression-free survival, time-to-progression, time-to-next treatment and overall survival when administered with various regimens.
The study will also monitor prognostic factors for overall survival and the spectrum of co-existing genetic abnormalities in this specific patient population.
AbbVie global oncology development vice-president and head Neil Gallagher said: “We look forward to the findings and to continue strengthening our ongoing research efforts to provide transformative therapies for patients with multiple myeloma and other blood cancers.”
